News Feed Item

Developments and Trends in Influenza Therapeutics (Technical Insights)

LONDON, Feb. 17, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:

Developments and Trends in Influenza Therapeutics (Technical Insights)

Emerging Technology and Major Partnerships in Influenza Vaccines

Influenza is a burgeoning problem across the entire globe, there is an increased need for new therapeutic methods. A whole host of technology platforms are being utilized to create non egg based vaccines. The world has not seen an influenza pandemic, and in terms of historical occurrences, we are several years overdue of one. There is a critical need for a universal vaccine, that has the potential to prevent multiple strains of influenza, so that yearly vaccinations can be eliminated and healthcare costs can be reduced. The main focus of the research service features the influenza vaccine market and the types of emerging technologies as well as developing partnerships over 2010-2013.

Key Findings

1. The Influenza therapeutics industry can be split into two main segments the antiviral industry and the influenza vaccines industry. There is a lot of funding for these industries to ensure protection for the global population against seasonal and pandemic influenza. Companies are striving to cover everyone, including the high-risk groups, such as children below the age of 2, adults above the age of 65, and people with preexisting medical conditions.
2. The influenza vaccine industry is witnessing a shift from the conventional egg-based vaccine development methods to more novel approaches. Some of them being DNA-based, recombinant subunit-based and even microbial vector-based approaches. These approaches are proving to be more cost effective and seem to have a higher rate of mass production, which is crucial if an influenza pandemic surfaces.
3. Efforts are being directed toward covering a boarder spectrum of viral strains than those presently being covered by seasonal influenza vaccines. The FDA has approved quadrivalent vaccines for distribution during the 2013-2014 seasonal influenza which covers Xstrains. There has been an increase in collaborations for the development of these 'universal vaccines' across the globe.
4. Developing new modes of administration of influenza vaccines is also an avenue that is being heavily explored by large and small biotechnology companies. They aim to eliminate the need for a needle and make it less invasive; this seems to be the primary focus of most research efforts. Some of the more nascent forms of administrating vaccines are oral vaccines and vaccine patches.
5. Looking more into R&D in a geographic perspective, there is a lot of funding going into influenza therapeutics in the US. In Europe, there is greater focus of R&D on new antiviral drug therapies and less focus on the vaccine industry. There is increasing focus on R&D in Asia Pacific and various new developments have taken place on the vaccine front, especially in countries, such as Singapore and Australia.

Research Scope

Influenza is a form of viral infection that can spread rapidly between people. It affects almost every age group and tends to impact the economy due to a significant decrease in productivity when employed professionals take sick leave. Seasonal epidemics usually affect the northern hemisphere (temperate regions) during the winter months. According to the Centers for Disease Control (CDC), worldwide influenza affects about Xmillion people annually and causes anywhere between X to Xdeaths. Children below the age of two, senior citizens ( over 65 years) and people who already have medical aliments, fall under the high-risk group. Seasonal influenza can be prevented by annual vaccinations against the prevalent strains for that season.

Influenza strains tend to rapidly mutate, aiding them in gaining resistance against the influenza vaccinations and antiviral drugs. Scientists in university laboratories and pharmaceuticals are trying to develop universal vaccines, that will provide patients boarder coverage against multiple influenza strains.

Looking at the larger picture, the influenza therapeutics industry has been experiencing many crucial changes. There are quite a few technical and business challenges that require immediate attention. The healthcare industry in general is moving toward preventative treatment options. Vaccine improvements will benefit all age groups as well as people with pre-existing conditions. The target demographics for these vaccines will increase , subsequently reducing epidemics across the globe.
Referencing sources on previous pandemics that have occurred, an influenza pandemic is currently overdue, which is an important point to note, as challenges with regards to pandemic influenza vaccinations need to be addressed immediately, to stay abreast with the situation of a potential pandemic.

The research service covers the following:
• Captures technologies used for influenza therapeutics and highlights innovations in the influenza vaccines and antiviral industry Orientation of research for existing and emerging diseases.
• Outlines the research portfolio, key trends and addresses the key technical challenges and key market challenges, and key performance
• Identifies opportunities in the field of targeted drug delivery for emerging and existing applications
• Provides strategic insights by highlighting the key performance indicators in the influenza therapeutics industry
• Highlights partnerships/collaborations at a global level for enhancing the development of influenza vaccines and entering into the market
• Provides strategic recommendations and conclusions, for companies working on influenza therapeutics to identify areas of growth
• Analytical Hierarchy Process (AHP) that analyzes the current research portfolio adopted by most companies for existing and emerging diseases.

Influenza Therapeutics Snapshot

Market Overview
• The influenza therapeutics market is valued at more than US $6 billion. (Frost & Sullivan Research Services)
• The Influenza vaccines segment is the largest and is expected to be $X billion
• The market is dominated by prophylactic vaccines for seasonal influenza treatments.
• Trivalent intramuscular vaccines form the largest market share under prophylactic vaccines.
• It is projected that quadrivalent vaccines will start dominating the market over the next five to seven years.

Influenza Therapeutics Market
Influenza Vaccines: X%
Antiviral Drugs: X%

Technology Overview
Presently influenza vaccines are based of two forms. One is the inactivated form that is usually delivered as an injection and the live attenuated form, that is delivered intranasally. The inactivated form can be further spilt into X different segments--the whole virus vaccine, split virus vaccine, and the subunit vaccine. These conventional methods predominantly use an egg-based production methodology. The present technology trend is moving toward reducing the egg-based production approach and delving deeper into cell-based production approaches.
The cell-based approaches are still under development and do not have any standardized protocols. There is also a lot of government, and private funded research taking place in small biotechnology companies and universities that are focusing on innovating novel technology platforms to produce and manufacture influenza vaccines. The conventional methods of production are not cost effective and take a long time to produce, approximately 6 to 9 months is needed for a flu vaccine to become available to the end user population. These novel and nascent technologies are aimed at solving challenges involving high cost of production and reduce the time required for the vaccine to become available to the end users.

Influenza Overview

• Influenza, commonly known as 'flu' is a respiratory infection caused by RNA viruses in the Orthomxyoviridae family.
• It is divided into three subtypes A, B and C, based on antigenic and genetic differences in their hemagglutinin (HA) and neuraminidase (NA) glycoproteins present on the surface of the virus.
• Seasonal human influenza is caused by types A and B, whereas type C occurs rarely as a mild disease in children
• Currently, the H1N1, H3N2, H5N1 strains of influenza are prevalent in humans and extensive research is being undertaken for developing therapeutics against these strains.

Influenza Subtype A
• Most of the common influenza epidemics affecting the human population are predominantly caused by this particular subtype of influenza. They are constantly mutating due to antigenic shifts. Two very important proteins that are present on the viral surface are hemagglutinin (HA) and neuraminidase (NA). At present, there are around X different subtypes of HA and 9 forms of NA. This form of influenza tends to undergo both the antigenic drift as well as the antigenic shift.

Influenza Subtype B
• This genus of virus, tends to mutate at a much slower rate than the influenza virus A. But unfortunately, most vaccinations do not give lasting immunity for this strain due to the manner in which they mutate.
• Mutations also happen due to antigenic shifts similar to Influenza virus A . This genus is found only in humans unlike Influenza virus A.

Influenza Subtype C
• This is a lot rarer compare to influenza virus A & B, but it has also been known to cause some epidemics which can be severe in intensity.

Table of Contents

Executive Summary 4
•Key Findings 5
•Research Scope 6
•Segmentation of Influenza Therapeutics 7
•Influenza Therapeutics Snapshot 8

Technology Snapshot 9
•Influenza Overview 10

Strategic Assessment of Industry Environment 11
•R& D Portfolio Analysis - Vaccines 12
• By Technology 13
• By Mode of Administration 19
•R& D Portfolio Analysis - Antivirals 20
•By Technology 21
•Industry Value Chain 22
•Stakeholder Overview 23
•Industry Participants -- By Technology 25
•Research Orientation 28
•Geographic Overview 30

Partnership & Alliances 32

R&D Budgetary Analysis 40

Environmental Analysis 48
•Technology Challenges 50
•Market Challenges 53

Strategic Evaluation of Research and Development Portfolio 57
•AHP – Analytical Hierarchy Process Based Tree 58

Contacts, Patents & DSD Tables 65

Appendix 77

The Frost & Sullivan Story 81

Read the full report:
Developments and Trends in Influenza Therapeutics (Technical Insights)

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
24Notion is full-service global creative digital marketing, technology and lifestyle agency that combines strategic ideas with customized tactical execution. With a broad understand of the art of traditional marketing, new media, communications and social influence, 24Notion uniquely understands how to connect your brand strategy with the right consumer. 24Notion ranked #12 on Corporate Social Responsibility - Book of List.
Established in 1998, Calsoft is a leading software product engineering Services Company specializing in Storage, Networking, Virtualization and Cloud business verticals. Calsoft provides End-to-End Product Development, Quality Assurance Sustenance, Solution Engineering and Professional Services expertise to assist customers in achieving their product development and business goals. The company's deep domain knowledge of Storage, Virtualization, Networking and Cloud verticals helps in delivering ...
In his session at @DevOpsSummit at 19th Cloud Expo, Robert Doyle, lead architect at eCube Systems, will examine the issues and need for an agile infrastructure and show the advantages of capturing developer knowledge in an exportable file for migration into production. He will introduce the use of NXTmonitor, a next-generation DevOps tool that captures application environments, dependencies and start/stop procedures in a portable configuration file with an easy-to-use GUI. In addition to captu...
Most of us already know that adopting new cloud applications can boost a business’s productivity by enabling organizations to be more agile and ready to change course in our fast-moving and connected digital world. But the rapid adoption of cloud apps and services also brings with it profound security threats, including visibility and control challenges that aren’t present in traditional on-premises environments. At the same time, the cloud – because of its interconnected, flexible and adaptable...
SYS-CON Events announced today that SoftNet Solutions will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. SoftNet Solutions specializes in Enterprise Solutions for Hadoop and Big Data. It offers customers the most open, robust, and value-conscious portfolio of solutions, services, and tools for the shortest route to success with Big Data. The unique differentiator is the ability to architect and...
In past @ThingsExpo presentations, Joseph di Paolantonio has explored how various Internet of Things (IoT) and data management and analytics (DMA) solution spaces will come together as sensor analytics ecosystems. This year, in his session at @ThingsExpo, Joseph di Paolantonio from DataArchon, will be adding the numerous Transportation areas, from autonomous vehicles to “Uber for containers.” While IoT data in any one area of Transportation will have a huge impact in that area, combining senso...
More and more brands have jumped on the IoT bandwagon. We have an excess of wearables – activity trackers, smartwatches, smart glasses and sneakers, and more that track seemingly endless datapoints. However, most consumers have no idea what “IoT” means. Creating more wearables that track data shouldn't be the aim of brands; delivering meaningful, tangible relevance to their users should be. We're in a period in which the IoT pendulum is still swinging. Initially, it swung toward "smart for smar...
Cognitive Computing is becoming the foundation for a new generation of solutions that have the potential to transform business. Unlike traditional approaches to building solutions, a cognitive computing approach allows the data to help determine the way applications are designed. This contrasts with conventional software development that begins with defining logic based on the current way a business operates. In her session at 18th Cloud Expo, Judith S. Hurwitz, President and CEO of Hurwitz & ...
@ThingsExpo has been named the Top 5 Most Influential M2M Brand by Onalytica in the ‘Machine to Machine: Top 100 Influencers and Brands.' Onalytica analyzed the online debate on M2M by looking at over 85,000 tweets to provide the most influential individuals and brands that drive the discussion. According to Onalytica the "analysis showed a very engaged community with a lot of interactive tweets. The M2M discussion seems to be more fragmented and driven by some of the major brands present in the...
In the next five to ten years, millions, if not billions of things will become smarter. This smartness goes beyond connected things in our homes like the fridge, thermostat and fancy lighting, and into heavily regulated industries including aerospace, pharmaceutical/medical devices and energy. “Smartness” will embed itself within individual products that are part of our daily lives. We will engage with smart products - learning from them, informing them, and communicating with them. Smart produc...
As ridesharing competitors and enhanced services increase, notable changes are occurring in the transportation model. Despite the cost-effective means and flexibility of ridesharing, both drivers and users will need to be aware of the connected environment and how it will impact the ridesharing experience. In his session at @ThingsExpo, Timothy Evavold, Executive Director Automotive at Covisint, will discuss key challenges and solutions to powering a ride sharing and/or multimodal model in the a...
In his keynote at 19th Cloud Expo, Sheng Liang, co-founder and CEO of Rancher Labs, will discuss the technological advances and new business opportunities created by the rapid adoption of containers. With the success of Amazon Web Services (AWS) and various open source technologies used to build private clouds, cloud computing has become an essential component of IT strategy. However, users continue to face challenges in implementing clouds, as older technologies evolve and newer ones like Docke...
SYS-CON Events announced today that Embotics, the cloud automation company, will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Embotics is the cloud automation company for IT organizations and service providers that need to improve provisioning or enable self-service capabilities. With a relentless focus on delivering a premier user experience and unmatched customer support, Embotics is the fas...
Just over a week ago I received a long and loud sustained applause for a presentation I delivered at this year’s Cloud Expo in Santa Clara. I was extremely pleased with the turnout and had some very good conversations with many of the attendees. Over the next few days I had many more meaningful conversations and was not only happy with the results but also learned a few new things. Here is everything I learned in those three days distilled into three short points.
Without lifecycle traceability and visibility across the tool chain, stakeholders from Planning-to-Ops have limited insight and answers to who, what, when, why and how across the DevOps lifecycle. This impacts the ability to deliver high quality software at the needed velocity to drive positive business outcomes. In his general session at @DevOpsSummit at 19th Cloud Expo, Eric Robertson, General Manager at CollabNet, will discuss how customers are able to achieve a level of transparency that e...